Department of Reproduction and Infertility, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Ann Med. 2022 Dec;54(1):2302-2308. doi: 10.1080/07853890.2022.2112069.
The aim of this study is to determine whether infertile couples who are carriers of chromosomal abnormalities have distinct cumulative clinical pregnancy and cumulative live birth rates among patients undergoing assisted reproductive technology (ART).
Design: A retrospective cohort study. Setting: Department of Reproduction and Infertility in Chengdu Women's and Children's Central Hospital.
A total of 112 couples were in the exposed group with chromosomal abnormalities, and 226 couples without chromosomal abnormalities were in the control group, totalling 338 cases enrolled from 1 January 2017 to 31 December 2020. The control group (infertile couples without chromosomal abnormalities) was 1:2 matched by female age, type of infertility (primary, secondary), and type of ART (IVF, ICSI, or IUI). The primary outcomes were cumulative clinical pregnancy rate and cumulative live birth rate.
The results indicated that chromosome abnormalities did not lead to significant differences in primary outcomes. The overall cumulative clinical pregnancy rate and cumulative live birth rate were not statistically different between the two groups (74.8% vs. 81.6%, = .150) and (65.4% vs. 69.1%, = .508). Further analysis revealed that there was also no significant difference in cumulative miscarriage rate between the two groups (13.9% vs. 20.3%, = .213).
There were no significant differences in the cumulative clinical pregnancy rate or cumulative live birth rate between infertile couples with or without chromosomal abnormalities. KEY MESSAGESThe prevalence of infertility is rising year by year worldwide.Carriers of chromosomal abnormalities undergoing ART have the similar cumulative clinical pregnancy rate or cumulative live birth rate.The data we analysed have a certain significance for clinical decision-making involving ART for couples with chromosomal abnormalities, and it provides a meaningful reference for patients and physicians in the selection of PGT.
本研究旨在确定接受辅助生殖技术(ART)的患者中,携带染色体异常的不孕夫妇的累积临床妊娠率和累积活产率是否存在差异。
设计:回顾性队列研究。地点:成都妇女儿童中心医院生殖与不孕科。
共有 112 对染色体异常的夫妇进入暴露组,226 对无染色体异常的夫妇进入对照组,共有 338 例患者于 2017 年 1 月 1 日至 2020 年 12 月 31 日入组。对照组(无染色体异常的不孕夫妇)按女性年龄、不孕类型(原发、继发)和 ART 类型(IVF、ICSI 或 IUI)1:2 配对。主要结局为累积临床妊娠率和累积活产率。
结果表明,染色体异常并未导致主要结局存在显著差异。两组间总体累积临床妊娠率和累积活产率无统计学差异(74.8%比 81.6%,=0.150)和(65.4%比 69.1%,=0.508)。进一步分析显示,两组间累积流产率也无显著差异(13.9%比 20.3%,=0.213)。
携带染色体异常的不孕夫妇与不携带染色体异常的不孕夫妇的累积临床妊娠率或累积活产率无显著差异。
全世界不孕症的患病率呈逐年上升趋势。接受 ART 的染色体异常携带者具有相似的累积临床妊娠率或累积活产率。我们分析的数据对涉及染色体异常夫妇的 ART 临床决策具有一定意义,为患者和医生在选择 PGT 方面提供了有意义的参考。